RPI-4610

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameRPI-4610
Drug Alias NameCancer ribozyme therapyAngiozymeRPI-4610
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsColorectal NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme Corp
Active IndicationsN/A
Inactive IndicationsColorectal NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia